Table 2.
Laboratory findings and clinical management of study participants in Eka Kotebe Hospital
| Variables | n (%) | |
|---|---|---|
| Oxygen therapy | Yes | 231 (49.9) |
| No | 232 (50.1) | |
| Noninvasive positive pressure ventilation | Yes | 26 (5.6) |
| No | 437 (94.4) | |
| Invasive ventilation | Yes | 37 (8.0) |
| No | 426 (92.0) | |
| Prone ventilation | Yes | 149 (32.2) |
| No | 314 (67.8) | |
| Tracheostomy inserted | Yes | 8 (1.7) |
| No | 455 (98.3) | |
| Chloroquine administered | Yes | 38 (8.2) |
| No | 425 (91.8) | |
| Antibiotics | Yes | 290 (62.6) |
| No | 173 (37.4) | |
| Steroids | Yes | 109 (23.5) |
| No | 354 (76.5) | |
| Prophylactic anticoagulant | Yes | 201 (43.4) |
| No | 262 (56.6) | |
| Full dose anticoagulant | Yes | 60 (13.0) |
| No | 403 (87.0) | |
| Vasopressor required | Yes | 32 (6.9) |
| No | 431 (93.1) | |
| ALC (N = 404) | < 1,000 | 140 (34.7) |
| ≥ 1,000 | 264 (65.3) | |
| AST (N = 356) | < 37 | 220 (61.8) |
| ≥ 37 | 136 (38.2) | |
| ALT (N = 360) | ≤ 63 | 292 (81.1) |
| > 63 | 68 (18.9) | |
| Length of stay (median, IQR) (15, 14–21) | ||
| Length of stay (days) | ≤ 15 | 255 (55.1) |
| > 15 | 208 (44.9) | |
ALC = absolute lymphocyte count; ALT = alanine transaminase; AST = aspartate transaminase; IQR = interquartile range.